Altimmune (ALT) Short term Debt (2012 - 2022)
Altimmune (ALT) reported Short term Debt of $4.3 million for Q1 2022, down 29.23% on a QoQ basis from $6.1 million in Q4 2021.
Altimmune (ALT) has 6 years of Short term Debt data on file, last reported at $4.3 million in Q1 2022.
- Quarterly Short term Debt changed N/A year-over-year to $4.3 million in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $4.3 million (changed N/A YoY) and the FY2021 annual result came in at $6.1 million, changed N/A from the prior year.
- Short term Debt declined to $4.3 million in Q1 2022 per ALT's latest filing, from $6.1 million in the prior quarter.
- Across five years, Short term Debt topped out at $6.1 million in Q4 2021 and bottomed at $4.3 million in Q1 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 4.31 Mn |
| Dec 31, 2021 | 6.09 Mn |
| Jun 30, 2015 | 249,491.00 |
| Mar 31, 2015 | 498,203.00 |
| Dec 31, 2014 | 746,146.00 |
| Jun 30, 2014 | 999,996.00 |
| Mar 31, 2014 | 999,996.00 |
| Dec 31, 2013 | 999,996.00 |
| Sep 30, 2013 | 999,996.00 |
| Jun 30, 2013 | 1.17 Mn |
| Mar 31, 2013 | 999,996.00 |
| Dec 31, 2012 | 749,997.00 |
| Sep 30, 2012 | 681,822.00 |
| Jun 30, 2012 | 454,548.00 |
| Mar 31, 2012 | 195,412.00 |